Compare WETH & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | NXTC |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 17.3M |
| IPO Year | 2020 | 2019 |
| Metric | WETH | NXTC |
|---|---|---|
| Price | $1.20 | $8.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 53.2K | ★ 199.4K |
| Earning Date | 04-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $45,136,818.00 | $22,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.40 | ★ N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $0.92 | $1.55 |
| 52 Week High | $3.68 | $15.74 |
| Indicator | WETH | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 65.26 |
| Support Level | $1.14 | $3.98 |
| Resistance Level | $1.49 | $8.72 |
| Average True Range (ATR) | 0.06 | 0.70 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 45.45 | 81.19 |
Wetouch Technology Inc is a business of research and development, manufacturing, and distribution of touchscreen displays to customers both in the PRC and overseas. The touchscreen products, which are manufactured by the Company, are mainly for use in financial terminals, automotive, Point of Sales, gaming, lottery, medical, Human-Machine Interface (HMI), and other specialized industries. The company sells touchscreen products both domestically in China and internationally, covering areas in Mainland China, including but not limited to the eastern, southern, northern, and southwest regions of Mainland China, Taiwan, South Korea, Germany, and other countries.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.